Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
Gilead Sciences (NASDAQ: GILD) and Terray Therapeutics have announced a strategic collaboration for discovering and developing novel small molecule therapies. Terray will utilize its tNova platform, which combines high-throughput chemical experimentation and AI-driven drug discovery, to work on targets selected by Gilead.
Under the agreement, Gilead receives exclusive options to license compounds and will handle further development and commercialization. Terray will receive an upfront payment plus potential milestone payments and tiered royalties on net sales. The transaction is expected to reduce Gilead's GAAP and non-GAAP 2024 EPS by approximately $0.01.
Gilead Sciences (NASDAQ: GILD) e Terray Therapeutics hanno annunciato una collaborazione strategica per scoprire e sviluppare nuove terapie a base di piccole molecole. Terray utilizzerà la sua tNova platform, che combina esperimenti chimici ad alta capacità e scoperta di farmaci guidata dall'IA, per lavorare su obiettivi selezionati da Gilead.
Secondo l'accordo, Gilead riceve opzioni esclusive per licenziare composti e gestirà ulteriori sviluppi e commercializzazione. Terray riceverà un pagamento iniziale più potenziali pagamenti per obiettivi raggiunti e diritti royalties scaglionati sulle vendite nette. Si prevede che la transazione ridurrà l'EPS GAAP e non GAAP di Gilead per il 2024 di circa $0.01.
Gilead Sciences (NASDAQ: GILD) y Terray Therapeutics han anunciado una colaboración estratégica para descubrir y desarrollar nuevas terapias de pequeñas moléculas. Terray utilizará su tNova platform, que combina la experimentación química de alto rendimiento y el descubrimiento de fármacos impulsado por IA, para trabajar en objetivos seleccionados por Gilead.
Según el acuerdo, Gilead recibe opciones exclusivas para licenciar compuestos y se encargará del desarrollo y comercialización posterior. Terray recibirá un pago inicial más posibles pagos por hitos y regalías escalonadas sobre las ventas netas. Se espera que la transacción reduzca el EPS GAAP y no GAAP de Gilead para 2024 en aproximadamente $0.01.
길리어드 사이언스(나스닥: GILD)와 테레 테라퓨틱스가 새로운 소분자 치료제를 발견하고 개발하기 위한 전략적 협력을 발표했습니다. 테레는 tNova 플랫폼을 활용하여 고속 화학 실험과 AI 기반 약물 발견을 결합하여 길리어드가 선택한 표적에 대해 작업할 것입니다.
합의에 따라, 길리어드는 화합물에 대한 독점 라이선스 옵션을 수령하며, 추가 개발 및 상업화는 길리어드가 담당합니다. 테레는 선불금과 함께 잠재적인 이정표 지급액 및 순매출에 대한 단계적 로열티를 받게 됩니다. 이번 거래는 길리어드의 2024년도 GAAP 및 비 GAAP EPS를 약 $0.01 감소시킬 것으로 예상됩니다.
Gilead Sciences (NASDAQ: GILD) et Terray Therapeutics ont annoncé une collaboration stratégique pour découvrir et développer de nouvelles thérapies à base de petites molécules. Terray utilisera sa tNova plateforme, qui combine l'expérimentation chimique à haut débit et la découverte de médicaments pilotée par l'IA, pour travailler sur des cibles sélectionnées par Gilead.
Selon l'accord, Gilead recevra des options exclusives pour licencier des composés et s'occupera du développement et de la commercialisation ultérieurs. Terray recevra un paiement initial plus des paiements potentiels liés aux étapes et des redevances en cascade sur les ventes nettes. On s'attend à ce que la transaction réduise les EPS GAAP et non GAAP de Gilead pour 2024 d'environ 0,01 $.
Gilead Sciences (NASDAQ: GILD) und Terray Therapeutics haben eine strategische Zusammenarbeit zur Entdeckung und Entwicklung neuartiger kleiner Molekültherapien bekannt gegeben. Terray wird seine tNova-Plattform nutzen, die hochdurchsatzchemische Experimente und KI-gesteuerte Wirkstoffforschung kombiniert, um an von Gilead ausgewählten Zielen zu arbeiten.
Im Rahmen der Vereinbarung erhält Gilead exklusive Optionen zur Lizenzierung von Verbindungen und wird die weitere Entwicklung und Vermarktung übernehmen. Terray erhält eine Vorauszahlung sowie potenzielle Meilensteinzahlungen und gestaffelte Lizenzgebühren auf den Nettoumsatz. Es wird erwartet, dass die Transaktion das GAAP- und non-GAAP-EPS von Gilead für 2024 um etwa 0,01 USD verringert.
- Strategic expansion into AI-driven drug discovery platform
- Exclusive licensing rights for developed compounds
- Risk-sharing structure with milestone-based payments
- Expected $0.01 reduction in 2024 EPS
Insights
This strategic partnership with Terray Therapeutics represents a significant move by Gilead to enhance its drug discovery capabilities through AI-driven technology. The tNova platform's combination of high-throughput experimentation and AI-powered analysis could substantially accelerate Gilead's drug development pipeline while reducing costs. The deal structure, with milestone payments and tiered royalties, effectively manages risk while maintaining upside potential.
The minimal EPS impact of
Terray's tNova platform represents a sophisticated approach to AI-driven drug discovery, combining traditional wet-lab experimentation with advanced computational methods. The platform's use of custom-generated data sets for training AI models addresses a common limitation in drug discovery AI - the quality and relevance of training data. By integrating high-throughput chemical experimentation with generative AI, the platform can potentially identify novel drug candidates more efficiently than traditional methods.
The iterative nature of their approach, using quantitative structure-activity relationship data, suggests a more reliable and validated drug discovery process compared to purely computational methods. This collaboration could significantly reduce the time and resources typically required in early-stage drug development.
-- Gilead and Terray Will Leverage Terray’s tNova Drug Discovery Platform to Identify Small Molecule Therapeutics Against Targets of Interest --
-- Gilead Has Exclusive Option to Develop and Commercialize Products from the Collaboration --
Terray’s tNova platform combines high-throughput chemical experimentation and computational analysis with a generative AI-driven drug discovery engine. The company’s iterative approach applies AI-empowered methods to an extensive library of quantitative, purpose-built, structure activity data to find the right molecules to solve complex problems in drug discovery.
“Next-generation, AI-driven platforms using custom-generated large, relevant data sets will serve as important tools in our efforts to shape the future of drug discovery in our ongoing pursuit of innovative treatments across our therapeutic areas of focus,” said Flavius Martin, M.D., Executive Vice President, Research, Gilead Sciences. “We are excited to collaborate with Terray and explore how their integrated discovery platform will complement our own internal research capabilities and expertise.”
“We’re proud to strategically partner with Gilead,” said Jacob Berlin, Ph.D., Chief Executive Officer, Terray Therapeutics. “We’re very excited to put tNova’s unique blend of experimentation and computation to work alongside the deep expertise of our collaborators at Gilead to find transformational small molecule therapeutics that bring relief to patients in need.”
Terms of the Agreement
Under the terms of the agreement, Terray will utilize the Terray tNova platform to discover and develop small molecule compounds against a set of targets selected by Gilead. If Gilead exercises its option to exclusively license the compounds directed to a target, Gilead will be responsible for further development and commercialization activities for products resulting from the collaboration. Terray will receive an upfront payment and is eligible to receive milestone payments associated with the achievement of preclinical, clinical, and sales milestones as well as tiered royalties on net sales of products commercialized by Gilead in connection with the collaboration.
Gilead does not exclude acquired IPR&D expenses from its non-GAAP financial measures. This transaction with Terray is expected to reduce Gilead’s GAAP and non-GAAP 2024 EPS by approximately
About Terray Therapeutics
Terray is an AI-powered biotechnology company with the technology, data, and mindset to radically change the way we discover and develop small molecule therapeutics. The company explores molecules and targets with a sophisticated integration of ultra-high throughput experimentation, generative AI, biology, medicinal chemistry, automation, and nanotechnology. Terray's platform uniquely blends experimentation and computation to deliver on the promise of generative AI for small molecule discovery—finding solutions to the toughest therapeutic challenges. To learn more about Terray, please visit terraytx.com and follow Terray Therapeutics on LinkedIn.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in
Gilead Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to realize the anticipated benefits from the collaboration; difficulties or unanticipated expenses in connection with the collaboration and the potential effects on Gilead’s earnings; the ability of the parties to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional trials, including those involving programs developed pursuant to the collaborations; the ability of the parties to file applications for regulatory approval or receive regulatory approvals in a timely manner or at all for the investigational programs developed pursuant to the collaborations, and the risk that any such approvals may be subject to significant limitations on use; the possibility that the parties may make a strategic decision to discontinue development of any of the investigational programs developed pursuant to the collaborations, and therefore these programs may never be successfully commercialized; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and other factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, as filed with the
Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.
For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).
View source version on businesswire.com: https://www.businesswire.com/news/home/20241217141411/en/
Gilead Info
Jessica Smith, Media
public_affairs@gilead.com
Jacquie Ross, Investors
investor_relations@gilead.com
Terray Info
Source: Gilead Sciences, Inc.
FAQ
How will the Terray collaboration affect GILD's 2024 earnings?
What rights does GILD have in the Terray Therapeutics collaboration?
What is the payment structure for the GILD-Terray collaboration?
What technology will be used in the GILD-Terray collaboration?
